[
    [
        {
            "time": "",
            "original_text": "智飞生物：智飞绿竹新型病毒疫苗和工程疫苗产业化基地项目正式开工",
            "features": {
                "keywords": [
                    "智飞生物",
                    "新型病毒疫苗",
                    "工程疫苗",
                    "产业化基地",
                    "开工"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "智飞生物：智飞绿竹新型病毒疫苗和工程疫苗产业化基地项目正式开工",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业周报：医美行业强化监管 安徽省IVD集采结果公布",
            "features": {
                "keywords": [
                    "医药生物",
                    "医美行业",
                    "强化监管",
                    "安徽省",
                    "IVD集采",
                    "结果公布"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物",
                    "医美"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药生物行业周报：医美行业强化监管 安徽省IVD集采结果公布",
                "Correlation": 4,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药行业：国内建议部分重点人群接种加强针",
            "features": {
                "keywords": [
                    "医药行业",
                    "国内",
                    "重点人群",
                    "接种",
                    "加强针"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业：国内建议部分重点人群接种加强针",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药与健康护理行业月报：智飞生物新冠疫苗III期数据优异 对变异株仍然有效",
            "features": {
                "keywords": [
                    "医药",
                    "健康护理",
                    "智飞生物",
                    "新冠疫苗",
                    "III期数据",
                    "变异株",
                    "有效"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "健康护理"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药与健康护理行业月报：智飞生物新冠疫苗III期数据优异 对变异株仍然有效",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "智飞生物(300122)：新冠疫苗拉动业绩快速增长 长期看好公司自研管线持续发力",
            "features": {
                "keywords": [
                    "智飞生物",
                    "新冠疫苗",
                    "业绩增长",
                    "自研管线",
                    "长期看好"
                ],
                "sentiment_score": 0.95,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "智飞生物(300122)：新冠疫苗拉动业绩快速增长 长期看好公司自研管线持续发力",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "西部证券维持智飞生物买入评级，公司2021中报点评：自研产品业绩贡献显着，新冠疫苗有望加速放量",
            "features": {
                "keywords": [
                    "西部证券",
                    "智飞生物",
                    "买入评级",
                    "2021中报",
                    "自研产品",
                    "业绩贡献",
                    "新冠疫苗",
                    "加速放量"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "西部证券维持智飞生物买入评级，公司2021中报点评：自研产品业绩贡献显着，新冠疫苗有望加速放量",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]